GSEA reveals significant enrichment of a 101-gene signature in patients with advanced high-grade serous tubo-ovarian cancer, suggesting potential biomarkers.
Figure S8 depicts GSEA for Millstein sub-signatures in the Charité cohort. Gene sets were incrementally increased by one gene at thetime (see color code). X-axis shows the NES and only the full 101-gene signature was significantly enriched.
No takes yet. Share an insight, caveat, or question.
Marchenko et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: